Form 4: Medpace Director Receives Stock Option Grant

Director Femida H. Gwadry-Sridhar was granted 1,110 stock options in Medpace Holdings, Inc. as part of standard equity compensation.

Summary

• Director Femida H. Gwadry-Sridhar received a grant of 1,110 stock options.
• The options have an exercise price of $415.27 per share.
• The grant date for these options is May 15, 2026.
• The options are set to expire on May 15, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon continued service on the board of directors.

Future Outlook

The options vest on the earlier of the day before the next annual meeting or the first anniversary of the grant date, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the clinical research organization (CRO) sector to ensure board retention and alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard equity compensation packages for independent directors at mid-to-large cap healthcare services companies.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of the next annual meeting or May 15, 2027.

Key Dates

Keywords

Medpace, MEDP, Form 4, Insider Trading, Stock Options, Director Compensation